You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Israeli company, which specializes in informatics and AI for agricultural and livestock genomics, is trading on the Tel Aviv Stock Exchange.
Talis, a point-of-care test developer, said that the principal purpose for the offering is to obtain additional capital to support its operations, among other purposes.
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
Shares of the Boston, Massachusetts-based company will begin trading Friday on the Nasdaq under ticker symbol MASS at $20 per share.
The company sells miniaturized mass spectrometers and microfluidic separations systems for use in applied markets and life science and drug research.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
The newly public company has attracted attention from both investors and competitors for its technology platform used in antibody discovery workflows.
In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.
The company is developing a blood-based test to detect more than 50 cancer types across all stages and identify a tumor's tissue of origin.
The cell analysis firm, which went public in July, saw service revenues fall 63 percent, offset by 17 percent growth in product revenues.
The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.
23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.
The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.
In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.